Oliver Zivanovic

Dr. Oliver Zivanovic


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MVMaria Vinsensia
Maria Vinsensia
RSRiccarda Schaub
Riccarda Schaub
EMEva Meixner
Eva Meixner
PHPhilipp Hoegen-Saßmannshausen
Philipp Hoegen-Saßmannshausen
NANathalie Arians
Nathalie Arians
JHJuliane Hörner-Rieber
Juliane Hörner-Rieber
Our study aims to identify the risk factors and dosimetry characteristics associated with capsular contracture. Methods: We retrospectively analyzed 118 women with breast cancer who underwent PMRT following an IBR between 2010 and 2022. Patients were treated with PMRT of 50.0–50.4 Gy in 25–28 fractions. Capsular contracture was categorized according to the Baker Classification for Reconstructed Breasts. Results: After a median follow-up of 22 months, the incidence of clinically relevant capsular contracture (Baker III–IV) was 22.9%. Overall, capsular contracture (Baker I–IV) occurred in 56 patients (47.5%) after a median of 9 months after PMRT. The rate of reconstruction failure/implant loss was 25.4%. In the univariate analysis, postoperative complications (prolonged pain, prolonged wound healing, seroma and swelling) and regional nodal involvement were associated with higher rates of capsular contracture (p = 0.017, OR: 2.5, 95% CI: 1.2–5.3 and p = 0.031, respectively). None of the analyzed dosimetric factors or the implant position were associated with a higher risk for capsular contracture. Conclusion: Postoperative complications and regional nodal involvement were associated with an increased risk of capsular contracture following breast reconstruction and PMRT, while none of the analyzed dosimetric factors were linked to a higher incidence. Additional studies are needed to identify further potential risk factors.

22 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RTRiku Togawa
Riku Togawa
HDHelena Dahm
Helena Dahm
MFManuel Feisst
Manuel Feisst
Hans-Peter SinnHans-Peter Sinn
Hans-Peter Sinn
AHAndre Hennigs
Andre Hennigs
Fabian RiedelFabian Riedel
Fabian Riedel
Background: The pretherapeutic assessment of axillary lymph node status is crucial in staging early breast cancer patients, significantly influencing their further treatment and prognosis. According to current guidelines, patients with clinically unsuspicious axillary status regularly undergo a biopsy of sentinel lymph nodes (SLNs), whereby metastasis is detected in up to 20% of cases. In recent years, the use of shear wave elastography (SWE) has been studied as an additional ultrasound tool for the non-invasive assessment of tumors in the breast parenchyma and axillary lymph nodes. Previous studies (examining the axilla in patients) have shown that metastases have significantly higher SWE values than benign nodes. Methods: This study aims to evaluate whether SWE can differentiate between tumor-free and metastatic-affected SLN ex vivo, i.e., by examining the pathological specimen. SWE was performed ex vivo on SLN specimens and compared with final histopathological results. Results: A total of 168 SLNs from 105 patients were measured using ex vivo SWE and subjected to standard histopathological processing. In this group, 17 metastases in 17 patients (16.19%) were detected. Tumor-free SLNs had a mean velocity of 1.33 ± 0.23 m/s, while metastatic nodes showed a mean velocity of 1.35 ± 0.29 m/s (p = 0.724). There was no significant difference in ex vivo SWE between benign and malignant SLNs in this population. Conclusions: Contrary to previous studies, this study did not find SWE effective in differentiating lymph node metastases. Further research is needed to clarify SWE’s potential role in axillary staging.

23 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Walid ShaalanWalid Shaalan
Walid Shaalan
KHKathrin Hassdenteufel
Kathrin Hassdenteufel
FHFabiola Hoppe
Fabiola Hoppe
Hans-Peter SinnHans-Peter Sinn
Hans-Peter Sinn
RTRiku Togawa
Riku Togawa
OZOliver Zivanovic
Oliver Zivanovic
Objective: This retrospective cohort study compares surgical outcomes among patients with endometrial carcinoma (EC) after the implementation of a robotic-assisted (RA) surgical program at a tertiary care center. Methods: A total of 122 EC patients who underwent surgery between March 2022 and February 2025 were included. Patients were divided into two cohorts based on the implementation of RA surgery: Group 1 (March 2022–August 2023) and Group 2 (September 2023–February 2025). Data collected included demographics, surgical approach, operative time, hospital stay, completion of staging procedures, and 30-day postoperative complications. Results: RA laparoscopy was used predominantly in Group 2, replacing conventional laparoscopy (CL). Laparotomy was significantly less frequent in group 2 (11.9% vs. 36.4%; p < 0.001). Among patients with FIGO stage I, all patients underwent minimally invasive surgery (MIS) in Cohort 2 (100% vs. 71.9%; p < 0.001). Median hospital stay was significantly shorter in Group 2 (3 days vs. 4 days; p < 0.001). A 30-day mortality occurred in one patient (n = 1) within the total study cohort (0.82%) and was attributed to pulmonary embolism on postoperative day 14 after RA laparoscopy. Rates of Grade ≥3 postoperative complications were similar (7.3% vs. 7.5%), as were wound complications (5.5% vs. 3%). The use of sentinel lymph node (SLN) mapping increased significantly in Group 2 (91% vs. 54.5%; p < 0.001). Completion staging procedures were significantly reduced in group 2 (9.1% vs. 0%; p = 0.017). Conclusions: The integration of RA laparoscopy significantly reduced laparotomy rates and hospital stays while increasing SLN mapping. These results support the continued adoption of RA laparoscopy to enhance MIS and improve patient outcomes.

6 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Walid ShaalanWalid Shaalan
Walid Shaalan
MEMohamed Eldesouky
Mohamed Eldesouky
TMTheresa Mokry
Theresa Mokry
ABArved Bischoff
Arved Bischoff
Hans-Peter SinnHans-Peter Sinn
Hans-Peter Sinn
Fabian RiedelFabian Riedel
Fabian Riedel
Background: Accurate intraoperative assessment of sentinel lymph node (SLN) status is critical for staging and guiding surgical management in gynaecological malignancies. Frozen-section histopathology remains the gold standard, but it is time-consuming and resource-intensive. Shear-wave elastography (SWE) quantifies tissue stiffness in real time and may offer a rapid alternative. Methods: In this prospective single-centre study, 63 women (median age 62 years) undergoing primary surgery with sentinel lymph node biopsy (SLNB) for endometrial, cervical, vulvar, or early ovarian carcinoma were enrolled. A total of 172 SLNs were excised, submerged in coupling gel, and scanned ex vivo using a 9 MHz linear probe. Results: A total of 172 SLNs underwent SWE (mean 2.7 nodes/patient). Endometrial primaries accounted for 58% of nodes, mostly retrieved by robotic-assisted surgery (71.8%). Node dimensions were significantly larger in malignant lesions for sonographic (long-axis: 13.02 ± 3.31 mm vs. 10.80 ± 3.28 mm; p = 0.002) and pathological long-axis measurements (11.45 ± 2.83 mm vs. 9.75 ± 2.61 mm; p = 0.004). Mean SWE velocities were similar between groups (1.381 ± 0.307 vs. 1.343 ± 0.236 m/s; p = 0.541). Histopathology identified metastases in 18% of SLNs, comprising macrometastases (7%), micrometastases (5%), and isolated tumour cells (6%). Conclusions: Although ex vivo SWE is rapid, reproducible, and integrates seamlessly into the sterile field, stiffness measurements alone lack sufficient discriminatory power for SLN staging in gynaecological cancers. Future research should focus on three-dimensional SWE, advanced radiomic analyses, and machine-learning algorithms to improve the detection of low-volume metastatic disease.

29 September 2026 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
Walid ShaalanWalid Shaalan
Walid Shaalan
NDNicola Dikow
Nicola Dikow
FKFelix K. F. Kommoss
Felix K. F. Kommoss
KSKatharina Smetanay
Katharina Smetanay
Nourhan HassanNourhan Hassan
Nourhan Hassan
Fabian RiedelFabian Riedel
Fabian Riedel
Background: Genetic counseling and germline genetic testing are essential components of ovarian cancer care; however, their implementation in routine clinical practice remains inconsistent. This study aimed to evaluate the utilization of genetic counseling and testing among patients with ovarian cancer and identify barriers to implementation within routine care. Methods: A single-center, retrospective questionnaire-based study was conducted among patients who underwent surgical treatment for ovarian malignancies between January 2021 and June 2025. Patient-reported data on information provision, referral pathways, organizational access, satisfaction, and barriers were linked with clinical and demographic characteristics. Descriptive analyses were performed, reflecting the exploratory nature of the study. A problem frequency (PF) framework, defined as the proportion of responses indicating a problem, was applied to identify and rank patient-reported barriers. Results: Of 321 identified patients, 61 were deceased prior to study initiation. Among 256 successfully contacted patients, 132 responded (51.6%). Overall, 115/132 (87.1%) reported receiving information regarding genetic counseling, primarily from hospital-based physicians (106/132; 80.3%). Among the 132 questionnaire respondents, 96/132 (72.7%) attended genetic counseling and 93/132 (70.5%) proceeded to genetic testing; pathogenic variants were identified in 26/93 tested patients (28.0%). Genetic counseling among respondents increased from 37.5% in 2021 to 94.7% in 2025. The majority of appointments were self-initiated. The most frequently reported barriers were limited information provision, appointment scheduling difficulties, and travel-related barriers, whereas emotional burden at the time of diagnosis was reported less frequently. Uptake was significantly associated with family history of breast and/or ovarian cancer, higher educational attainment, and parity. Notably, nearly half of the participants who had not attended genetic counseling (17/36;47.2%) reported reconsidering uptake after completing the questionnaire. Conclusion: Despite recommendations for universal genetic counseling in ovarian cancer care, gaps in implementation remain evident in routine clinical practice. Organizational and informational barriers represent prominent obstacles to uptake. Our findings highlight the potential value of standardized referral pathways, proactive information provision, and repeated patient engagement to facilitate access to genetic services.

27 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
RTRiku Togawa
Riku Togawa
DBDina Batarseh
Dina Batarseh
HDHelena Dahm
Helena Dahm
TDThomas M Deutsch
Thomas M Deutsch
AHAndre Hennigs
Andre Hennigs
Fabian RiedelFabian Riedel
Fabian Riedel
Background/Objectives: To evaluate the diagnostic accuracy of different imaging modalities in patients with pathologic nipple discharge. Methods: This is a single-centre retrospective analysis of patients with pathologic nipple discharge. All performed imaging modalities were reviewed for their sensitivity and specificity in correctly diagnosing malignancy, as well as lesions with uncertain malignant potential (B3). Results: Of 388 patients, pathology or follow-up confirmed 41 cases of malignancy (15 breast cancer, 26 ductal carcinoma in situ (DCIS)), 151 cases of B3 lesions, and 196 benign cases. The combination of ultrasound and mammography/tomosynthesis achieved a sensitivity of 82.5% (95% CI 68.1–91.3) and a specificity of 83.5% (77.4–88.2) for the detection of malignancy. For the classification of B3 lesions as suspicious (BI-RADS 4/5), the sensitivity and specificity were 33.8% (26.7–41.7) and 83.5% (77.4–88.2), respectively. Ductography demonstrated a sensitivity of 89.3% (72.8–96.3) and a specificity of 13.3% (8.2–20.8) for malignancy, while MRI showed a sensitivity of 71.4% (45.4–88.3) and a specificity of 90.0% (76.9–96.0). In classifying B3 lesions as suspicious, ductography reached a sensitivity of 94.8% (89.7–97.5) and a specificity of 13.3% (8.2–20.8), compared to 75.9% (57.9–87.8) and 90.0% (76.9–96.0), respectively, for MRI. Conclusions: While the combination of ultrasound and mammography/tomosynthesis correctly classified 82.5% of breast malignancies associated with pathologic nipple discharge as suspicious, their sensitivity for classifying B3 lesions as suspicious was only moderate (33.8%). In patients with negative or inconclusive conventional imaging but persistent clinical suspicion, MRI may be considered as an additional diagnostic tool, whereas ductography, given its low specificity, is of limited value for assessing lesion dignity and may primarily serve to localize the affected duct prior to surgery. Further research is needed to determine which diagnostic modality provides the greatest benefit in specific cases.